– USA, CA – T-knife Therapeutics, Inc., a biopharmaceutical company developing T cell receptor (TCR) engineered T cell therapies (TCR-T) to fight cancer, announced the appointment of Christoph Broja to its Board of Directors.
About Christoph Broja
Christoph Broja is a Partner at EQT Life Sciences in Munich, where he leads investments in biotech, pharmaceuticals, medical devices, and diagnostics, with a focus on early-stage and growth opportunities. Known for his collaborative, curiosity-driven approach, he is recognized for bringing an investor-first perspective to life sciences venture capital and for his leadership in advancing the European biotech ecosystem. He is a board member at Tubulis GmbH and previously served on the board of Cardior Pharmaceuticals, among others. Before joining EQT in 2022, Mr. Broja was a Principal at Gurnet Point Capital in Boston, where he contributed to investments across biopharma and molecular diagnostics and held board roles at several innovative healthcare companies. Before that, he worked at B-Flexion Capital in London, and he started his career as an investment analyst at the private equity firm Franz Haniel & Cie. in Germany. Mr. Broja holds a degree in Business Administration from Friedrich Schiller University Jena and is a Chartered Financial Analyst (CFA).
About T-knife Therapeutics
T-knife is a biopharmaceutical company dedicated to developing T cell receptor (TCR) engineered T cell therapies (TCR-Ts) to deliver broad, deep, and durable responses to solid tumor cancer patients. The company’s unique approach leverages its proprietary platforms and synthetic biology capabilities to design the next generation of supercharged TCR-Ts with best-in-class potential.
The company’s lead program, TK-6302, is a supercharged PRAME targeting TCR-T that includes novel enhancements to improve T cell fitness and persistence, overcome the immunosuppressive tumor micro-environment, and improve durability of response. The company plans to submit a Clinical Trial Application (CTA) in the fall of 2025 to initiate a Phase 1 clinical study of TK-6302 in 2026.
T-knife was founded by leading T cell and immunology experts utilizing technology developed at the Max Delbrück Center for Molecular Medicine together with Charité – Universitätsmedizin Berlin, is led by an experienced management team, and is supported by a leading group of international investors, including Andera Partners, EQT Life Sciences, RA Capital Management, and Versant Ventures.
For more: https://t-knife.com/
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.